|
1
|
Malumbres M and Barbacid M: To cycle or
not to cycle: a critical decision in cancer. Nat Rev Cancer.
1:222–231. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lee J, Choi H, Kim KH, et al: Synthesis
and biological evaluation of 3,5-diaminoindazoles as
cyclin-dependent kinase inhibitors. Bioorg Med Chem Lett.
18:2292–2295. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shin HC, Song DW, Baek WK, et al:
Anticancer activity and differentially expressed genes in head and
neck cancer cells treated with a novel cyclin-dependent kinase
inhibitor. Chemotherapy. 55:353–362. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kim S, Lee J, Jang BC, Kwon TK and Park
JW: BAI, a novel cyclin-dependent kinase inhibitor induces
apoptosis in A549 cells through activation of caspases and
inactivation of Akt. J Cell Biochem. 114:282–293. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bharate SB, Singh B and Vishwakarma RA:
Modulation of K-Ras signaling by natural products. Curr Med Chem.
19:2273–2291. 2012.PubMed/NCBI
|
|
6
|
Almoguera C, Shibata D, Forrester K,
Martin J, Arnheim N and Perucho M: Most human carcinomas of the
exocrine pancreas contain mutant c-K-ras genes. Cell. 53:549–554.
1988. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nelson MA, Wymer J and Clements N Jr:
Detection of K-ras gene mutations in non-neoplastic lung tissue and
lung cancers. Cancer Lett. 103:115–121. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gibbs JB, Oliff A and Kohl NE:
Farnesyltransferase inhibitors: Ras research yields a potential
cancer therapeutic. Cell. 77:175–178. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tamanoi F: Inhibitors of Ras
farnesyltransferases. Trends Biochem Sci. 18:349–353. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Travis J: Novel anticancer agents move
closer to reality. Science. 260:1877–1878. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Carloni V, Vizzutti F and Pantaleo P:
Farnesyltransferase inhibitor, ABT-100, is a potent liver cancer
chemopreventive agent. Clin Cancer Res. 11:4266–4274. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin NH, Wang L, Cohen J, et al: Synthesis
and biological evaluation of
4-[(3-methyl-3H-imidazol-4-yl)-(2-phenylethynyl-benzyloxy)-
methyl]-benzonitrile as novel farnesyltransferase inhibitor. Bioorg
Med Chem Lett. 13:3821–3825. 2003.
|
|
13
|
Lin NH, Wang L, Wang X, et al: Synthesis
and biological evaluation of
1-benzyl-5-(3-biphenyl-2-yl-propyl)-1H-imidazole as novel
farnesyltransferase inhibitor. Bioorg Med Chem Lett. 14:5057–5062.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim HS, Kim JW, Gang J, et al: The
farnesyltransferase inhibitor, LB42708, inhibits growth and induces
apoptosis irreversibly in H-ras and K-ras-transformed rat
intestinal epithelial cells. Toxicol Appl Pharmacol. 215:317–329.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Balasis ME, Forinash KD, Chen YA, et al:
Combination of farnesyltransferase and Akt inhibitors is
synergistic in breast cancer cells and causes significant breast
tumor regression in ErbB2 transgenic mice. Clin Cancer Res.
17:2852–2862. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Krzykowska-Petitjean K, Malecki J, Bentke
A, Ostrowska B and Laidler P: Tipifarnib and tanespimycin show
synergic proapoptotic activity in U937 cells. J Cancer Res Clin
Oncol. 138:537–544. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sackova V, Kulikova L, Kello M, Uhrinova I
and Fedorocko P: Enhanced antiproliferative and apoptotic response
of HT-29 adenocarcinoma cells to combination of photoactivated
hypericin and farnesyltransferase inhibitor manumycin A. Int J Mol
Sci. 12:8388–8405. 2011. View Article : Google Scholar
|
|
18
|
Edamatsu H, Gau CL, Nemoto T, Guo L and
Tamanoi F: Cdk inhibitors, roscovitine and olomoucine, synergize
with farnesyltransferase inhibitor (FTI) to induce efficient
apoptosis of human cancer cell lines. Oncogene. 19:3059–3068. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee H, Lee J, Lee S, et al: A novel class
of highly potent, selective, and non-peptidic inhibitor of Ras
farnesyltransferase (FTase). Bioorg Med Chem Lett. 11:3069–3072.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hetz C: The unfolded protein response:
controlling cell fate decisions under ER stress and beyond. Nat Rev
Mol Cell Biol. 13:89–102. 2012.PubMed/NCBI
|
|
21
|
Simon HU, Haj-Yehia A and Levi-Schaffer F:
Role of reactive oxygen species (ROS) in apoptosis induction.
Apoptosis. 5:415–418. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Le Bras M, Rouy I and Brenner C: The
modulation of interorganelle cross-talk to control apoptosis. Med
Chem. 2:1–12. 2006.PubMed/NCBI
|
|
23
|
Bodur C and Basaga H: Bcl-2 inhibitors:
emerging drugs in cancer therapy. Curr Med Chem. 19:1804–1820.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ili CG, Brebi P, Tapia O, et al: Cellular
FLICE-like inhibitory protein long form (c-FLIPL) overexpression is
related to cervical cancer progression. Int J Gynecol Pathol.
32:316–322. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Khosravi-Far R and Der CJ: The Ras signal
transduction pathway. Cancer Metastasis Rev. 13:67–89. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cohen LH, Pieterman E, van Leeuwen RE, et
al: Inhibitors of prenylation of Ras and other G-proteins and their
application as therapeutics. Biochem Pharmacol. 60:1061–1068. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Moasser MM, Sepp-Lorenzino L, Kohl NE, et
al: Farnesyl transferase inhibitors cause enhanced mitotic
sensitivity to taxol and epothilones. Proc Natl Acad Sci USA.
95:1369–1374. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Smalley KSM and Eisen TG: Farnesyl
transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and
enhances chemosensitivity to cisplatin in melanoma cells. Int J
Cancer. 105:165–175. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wesierska-Gadek J, Maurer M and Schmid G:
Inhibition of farnesyl protein transferase sensitizes human MCF-7
breast cancer cells to roscovitine-mediated cell cycle arrest. J
Cell Biochem. 102:736–747. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Singha PK, Pandeswara S, Venkatachalam MA
and Saikumar P: Manumycin A inhibits triple-negative breast cancer
growth through LC3-mediated cytoplasmic vacuolation death. Cell
Death Dis. 4:e4572013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mahoney E, Lucas DM, Gupta SV, et al: ER
stress and autophagy: new discoveries in the mechanism of action
and drug resistance of the cyclin-dependent kinase inhibitor
flavopiridol. Blood. 120:1262–1273. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kuo PL, Chen CY and Hsu YL:
Isoobtusilactone A induces cell cycle arrest and apoptosis through
reactive oxygen species/apoptosis signal-regulating kinase 1
signaling pathway in human breast cancer cells. Cancer Res.
67:7406–7420. 2007. View Article : Google Scholar
|
|
33
|
Yodkeeree S, Sung B, Limtrakul P and
Aggarwal BB: Zerumbone enhances TRAIL-induced apoptosis through the
induction of death receptors in human colon cancer cells: Evidence
for an essential role of reactive oxygen species. Cancer Res.
69:6581–6589. 2009. View Article : Google Scholar
|
|
34
|
Min KJ, Kim HS, Park EJ and Kwon TK:
Melatonin enhances thapsigargin-induced apoptosis through reactive
oxygen species-mediated upregulation of CCAAT-enhancer-binding
protein homologous protein in human renal cancer cells. J Pineal
Res. 53:99–106. 2012. View Article : Google Scholar
|
|
35
|
She M, Yang H, Sun L and Yeung SC: Redox
control of manumycin A-induced apoptosis in anaplastic thyroid
cancer cells: involvement of the xenobiotic apoptotic pathway.
Cancer Biol Ther. 5:275–280. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pan J, She M, Xu ZX, Sun L and Yeung SC:
Farnesyltransferase inhibitors induce DNA damage via reactive
oxygen species in human cancer cells. Cancer Res. 65:3671–3681.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Slee EA, Zhu H, Chow SC, MacFarlane M,
Nicholson DW and Cohen GM: Benzyloxycarbonyl-Val-Ala-Asp (OMe)
fluoromethylketone (Z-VAD.FMK) inhibits apoptosis by blocking the
processing of CPP32. Biochem J. 315:21–24. 1996.PubMed/NCBI
|
|
38
|
Yang B, El Nahas AM, Fisher M, et al:
Inhibitors directed towards caspase-1 and -3 are less effective
than pan caspase inhibition in preventing renal proximal tubular
cell apoptosis. Nephron Exp Nephrol. 96:e39–e51. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yang PM, Tseng HH, Peng CW, Chen WS and
Chiu SJ: Dietary flavonoid fisetin targets caspase-3-deficient
human breast cancer MCF-7 cells by induction of
caspase-7-associated apoptosis and inhibition of autophagy. Int J
Oncol. 40:469–478. 2012.PubMed/NCBI
|
|
40
|
Sawai H: Differential effects of caspase
inhibitors on TNF-induced necroptosis. Biochem Biophys Res Commun.
432:451–455. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Uchiyama R, Kawamura I, Fujimura T, et al:
Involvement of caspase-9 in the inhibition of necrosis of RAW 264
cells infected with Mycobacterium tuberculosis. Infect Immun.
75:2894–2902. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhou Q, Snipas S, Orth K, Muzio M, Dixit
VM and Salvesen GS: Target protease specificity of the viral serpin
CrmA. Analysis of five caspases. J Biol Chem. 272:7797–7800. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Garcia-Calvo M, Peterson EP, Leiting B,
Ruel R, Nicholson DW and Thornberry NA: Inhibition of human
caspases by peptide-based and macromolecular inhibitors. J Biol
Chem. 273:32608–32613. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Schimmer AD, Dalili S, Batey RA and Riedl
SJ: Targeting XIAP for the treatment of malignancy. Cell Death
Differ. 13:179–188. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zinkel S, Gross A and Yang E: BCL2 family
in DNA damage and cell cycle control. Cell Death Differ.
13:1351–1359. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Jonsson G, Paulie S and Grandien A: High
level of cFLIP correlates with resistance to death receptor-induced
apoptosis in bladder carcinoma cells. Anticancer Res. 23:1213–1218.
2003.PubMed/NCBI
|
|
47
|
Longley DB, Wilson TR, McEwan M, et al:
c-FLIP inhibits chemotherapy-induced colorectal cancer cell death.
Oncogene. 25:838–848. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Thomas S, Quinn BA, Das SK, et al:
Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther
Targets. 17:61–75. 2013. View Article : Google Scholar
|
